The company, based in Fort Myers, Florida, said that it plans to use the net proceeds from the offering for general corporate purposes.
The company plans to offer 5.5 million shares of its common stock at $23.25 per share, raising around $127.9 million.
The company will use the proceeds for working capital and to repay around $12.4 million of its term loan.
The firm is selling more than 5.2 million shares at an offering price of $19 per share.
To help fund the acquisition, Yourgene Health is planning to sell at least £10.0 million in newly issued shares to institutional investors.
The firm expects to offer nearly 5 million shares and also noted that this week it entered into an amended credit facility.
The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.
Genfit expects to use part of the gross proceeds from the offering to advance the commercial development of a diagnostic test to identify patients with nonalcoholic steatohepatitis.
Proceeds will be used for the anticipated regulatory submission of its gene panel test for urinary tract infections and drug resistance, among other things.
The company said it will offer 4.5 million shares for $23 per share and intends to use the net proceeds for working capital and general corporate purposes.